Stay updated on DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Sign up to get notified when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.

Latest updates to the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4. This indicates a minor documentation/versioning update rather than changes to the study data or displayed content.SummaryDifference0.0%

- Check28 days agoChange DetectedResults were posted on 2026-05-06 for the SPiReL trial, with detailed efficacy and safety outcomes. The update includes measures such as Objective Response Rate, Duration of Response, Time to Next Treatment, and related biomarker analyses.SummaryDifference2%

- Check42 days agoChange DetectedThe page’s displayed site revision has been updated from v3.5.2 to v3.5.3, indicating a general platform/UI release rather than a change to the study record content.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check64 days agoChange DetectedNo additions or deletions were detected on the page.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.